The effect of lidocaine spray in reducing ophthalmic neuralgia in patients with multiple sclerosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231029059896N1

Enrollment

Registered

2023-11-13

Start date

2023-10-23

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention group : 10% lidocaine nasal spray, 2 puffs of the spray (equivalent to 0.2 mg) to be used during pain..

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Definite MS confirmed by MRI Confirmation of ophthalmic neuralgia without response to drug treatment Performing a lidocaine sensitivity test and proving the absence of lidocaine sensitivity The patient's willingness to participate in the study and obtain informed consent The patient's MS must be of the relapsing remitting type and must have been approved by a neurologist.

Exclusion criteria

Exclusion criteria: Occurrence of drug side effects Worsening of symptoms. Patient dissatisfaction More than three months have passed since the diagnosis of their disease and they have entered the chronic phase

Design outcomes

Primary

Measure	Time frame
The primary outcome of the patient's pain intensity based on Visual Analogue Scale (VAS) criteria. Timepoint: Before using the spray. Method of measurement: These outcomes are measured by a neurologist based on the VAS.	—

Secondary

Measure	Time frame
Measurement of pain-free time after each use of the spray?. Timepoint: The pain-free period after using the spray during pain is recorded in 0-6-12-24 hours and more than one week from the patients. Method of measurement: These outcomes are measured by the evaluator, who is a final year medical student who is not aware of the assignment of the subjects to each of the two allocation groups and the drugs used. Pain-free time after using the spray during pain in hours 0-6-12-24 and more than one week of patients are recorded. The instrument for measuring this variable is based on the patient's statements and its unit is amount of hours.	—

Measure

Time frame

Measurement of pain-free time after each use of the spray?. Timepoint: The pain-free period after using the spray during pain is recorded in 0-6-12-24 hours and more than one week from the patients. Method of measurement: These outcomes are measured by the evaluator, who is a final year medical student who is not aware of the assignment of the subjects to each of the two allocation groups and the drugs used. Pain-free time after using the spray during pain in hours 0-6-12-24 and more than one week of patients are recorded. The instrument for measuring this variable is based on the patient's statements and its unit is amount of hours.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Maryam Daneshian

Mazandaran University of Medical Sciences

daneshian8@gmail.com+98 11 3304 4001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026